Juvenile neuronal ceroid lipofuscinosis is a childhood-onset neurodegenerative disease with prominent symptoms comprising a pediatric dementia syndrome: intellectual decline, mood and behavioral impairments, and loss of adaptive skills. We review the history of neurobehavioral features in juvenile neuronal ceroid lipofuscinosis and the work of the University of Rochester Batten Center to characterize the extent and progression of neurobehavioral symptoms over the disease course, and discuss the relevance of neurobehavioral studies as an aid to understanding the clinical phenotype of juvenile Batten disease and potential targets for intervention.
PhillipsSNBenedictJWWeimerJMPearceDA. CLN3, the protein associated with batten disease: structure, function and localization. J Neurosci Res. 2005;79:573–583.
2.
WilliamsR. NCL incidence and prevalence data. In: MoleSWilliamsREGoebelH, eds. The Neuronal Ceroid Lipofuscinoses: Batten Disease. 2nd ed. Oxford: Oxford University Press; 2011.
3.
CialoneJAdamsHAugustineE. Females experience a more severe disease course in Batten disease. J Inherit Metabol Dis. 2011;35:549–555.
4.
StengelO.Report about a strange illness in four siblings in the vicinity of Røros [in Norwegian]. Hager P, Andersen T, trans. Eyr. 1826;1:347–352.
5.
BattenF.Cerebral degeneration with symmetrical changes in the maculae in two members of a family. Paper presented at Transactions of the Opthalmological Society of the United Kingdom. Volume XXIII. Session 1902–1903; London.
6.
BäckmanMLSantavuoriPRÅbergLEAronenET. Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2005;49:25–32.
7.
BoustanyRMFilipekP. Seizures, depression and dementia in teenagers with Batten disease. J Inherit Metab Dis. 1993;16:252–255.
8.
LauronenLMunroePBJärveläI. Delayed classic and protracted phenotypes of compound heterozygous juvenile neuronal ceroid lipofuscinosis. Neurology. 1999;52:360–365.
9.
SantavuoriPLinnankiviTJaekenJVanhanenS-LTelakiviTHeiskalaH. Psychological symptoms and sleep disturbances in neuronal ceroid-lipofuscinoses (NCL). J Inherit Metab Dis. 1993;16:245–248.
10.
CrowYJTolmieJLHowatsonAGPatrickWJAStephensonJBP. Batten disease in the west of Scotland 1974-1995 including five cases of the juvenile form with granular osmiophilic deposits. Neuropediatrics. 1997;28:140–144.
LamminrantaSÅbergLEAuttiT. Neuropsychological test battery in the follow-up of patients with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2001;45:8–17.
13.
MarshallFde BlieckEMinkJ. Unified Batten Disease Rating Scale: description and reliability. Ann Neurol. 2004;56(suppl 8):S102.
14.
MarshallFJde BlieckEAMinkJW. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology. 2005;65:275–279.
15.
Psychological Corporation. Wechsler Intelligence Scale for Children–Fourth Edition. Manual. San Antonio: The Psychological Corporation; 2003.
16.
SheslowDAdamsW. WRAML2. Wide Range Assessment of Memory and Learning. 2nd ed. Wilmington, DE: Wide Range Inc; 2003.
17.
LezakM. Neuropsychological Assessment. 3rd ed. New York: Oxford University Press; 1995.
18.
VarniJSeidMRodeC. The PedsQL™: measurement model for the Pediatric Quality of Life Inventory™. Med Care. 1999;37:126–139.
19.
VarniJWShermanSABurwinkleTMDickinsonPEDixonP. The PedsQL™ Family Impact Module: preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:1–6.
ReynoldsCRBiglerED. Test of Memory and Learning. Examiner's Manual. Austin: Pro-Ed; 1994.
23.
Psychological Corporation. WAIS-III, WMS-III. Technical Manual. San Antonio: The Psychological Corporation; 2002.
24.
SemelEWiigEHSecordWA. Clinical Evaluation of Language Fundamentals—Third Edition. Technical Manual. San Antonio: The Psychological Corporation; 1995.
25.
RothbergPGRamirez-MontealegreDFrazierSDPearceDA. Homogeneous polymerase chain reaction nucleobase quenching assay to detect the 1-kbp deletion in CLN3 that causes Batten disease. J Mol Diagn. 2004;6:260–263.
26.
WilliamsRMoleS. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79:183–191.
27.
StatSoft, Inc. STATISTICA (data analysis software system) [computer program]. Version 10.2011.
28.
AdamsHde BlieckEDureL. Obsessive/compulsive symptoms in juvenile neuronal ceroid lipofuscinosis (Batten disease). Ann Neurol. 2004;56(suppl 8):S127.
29.
AdamsHde BlieckEDureLMarshallFMinkJPearceDA. Neuropsychological and behavioral symptoms in juvenile neuronal ceroid lipofuscinosis (NCL-3; Batten's disease). Neurology. 2004;62(suppl 5):A68–A69.
30.
AdamsHde BlieckEAMinkJW. Standardized assessment of behavior and adaptive living skills in juvenile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2006;48:259–264.
31.
AdamsHBeckCLevyE. Genotype does not predict severity of behavioral phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease). Dev Med Child Neurol. 2010;52:637–643.
32.
AdamsHKwonJMarshallFJde BlieckEAPearceDAMinkJW. Neuropsychological symptoms of Juvenile-onset Batten disease: experiences from two studies. J Child Neurol. 2007;22:621–627.
33.
LabbeEE. Emotional states and perceived family functioning of caregivers of chronically ill children. Psychol Rep. 1996;79:1233–1234.
34.
LabbeEELopezIMurphyLO'BrienC. Optimism and psychosocial functioning in caring for children with Battens and other neurological diseases. Psychol Rep. 2002;90(3 Pt 2):1129–1135.
35.
AdamsHdeBlieckEKwonJ. Quality of life in Batten disease: affected children, parents, and siblings. Paper presented at: 11th International Congress on Neuronal Ceroid Lipofuscinosis (Batten Disease)July 2007; Rochester, NY.
BaronIS. Neuropsychological Evaluation of the Child. Oxford: Oxford University Press; 2004.
38.
ShapiroEBalthazorM. Metabolic and neurodegenerative disorders. In: YeatesKRisMTaylorH, eds. Pediatric Neuropsychology: Research, Theory, and Practice. New York: Guilford; 2000:171–205.
39.
CialoneJAugustineEFNewhouseNVierhileAMarshallFJMinkJW. Quantitative telemedicine ratings in Batten disease: implications for rare disease research. Neurology. 2011;77:1808–1811.
40.
Batten Disease Support and Research Association, FDA Office of Orphan Products Development, University of Rochester. Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JUMP). ClinicalTrials.gov Identifier: NCT01399047Accessed May 6, 2013, ClinicalTrials.gov.
41.
BartonCMorrisRRothlindJYaffeK. Video-telemedicine in a memory disorders clinic: evaluation and management of rural elders with cognitive impairment. Telemed J E-Health. 2011;17:789–793.
42.
BreitlingLPWolfMMullerHRaumEKliegelMBrennerH. Large-scale application of a telephone-based test of cognitive functioning in older adults. Dement Geriatr Cogn Disord. 2010;30:309–316.
43.
MundtJCGeraltsDSMooreHK. Dial “T” for testing: Technological flexibility in neuropsychological assessment. Telemed J E-Health. 2006;12:317–323.
44.
StainHJPayneKThienelRMichiePCarrVKellyB. The feasibility of videoconferencing for neuropsychological assessments of rural youth experiencing early psychosis. J Telemed Telecare. 2011;17:328–331.
45.
BäckmanMLÅbergLEAronenETSantavuoriPR. New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses—a pilot study. Eur J Paediatr Neurol. 2001;5(suppl A):163–166.
46.
LogsonRMcCurrySTeriL. Evidence-based psychological treatments for disruptive behavior in individuals with dementia. Psychol Aging. 2007;22:28–36.
PetersCCharnasLRTanY. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104:881–888.
